Prophages are viral genomes that have merged into bacterial genomes. They can occasionally reanimate and release new virus particles, endangering the bacteria that host them. CRISPR-Cas systems, which act as an adaptive immune system in bacteria, defend against these assaults by targeting and slicing viral DNA.
However, researchers at ETH Zurich discovered that bacteria also employ a second immunity mechanism, which they dubbed the type III-A CRISPR-Cas system, according to a study that was published in the journal "Cell." This method differs from the conventional type II CRISPR-Cas system in that it uses a distinct set of proteins and targets RNA instead of DNA.
The type III-A CRISPR-Cas system was studied by researchers led by Martin Jinek, professor of biochemistry at ETH Zurich, using the model bacterium Escherichia coli (E. coli). They discovered that the system protects E. coli from the virus known as P1 by identifying and destroying viral RNA.
A single protein known as Csm6 is responsible for the mechanism's operation. Csm6 has previously been shown to perform other tasks, but its participation in immunity was unexpected. Csm6 searches for RNA sequences that resemble the bacterial genome and targets viral RNA for destruction when bound to guide RNA molecules.
The type III-A CRISPR-Cas system is particularly interesting because it does not require the CRISPR RNA to match the goal RNA perfectly. Instead, it employs a wobbly base pairing method that enables the targeting of a variety of RNA sequences with a single guide RNA.
This wobble-based targeting technique gives the type III-A CRISPR-Cas system a competitive advantage when dealing with quickly evolving viruses. Viruses frequently change their RNA sequences to avoid detection by other immunological mechanisms. The type III-A CRISPR-Cas system, however, can identify and target a larger range of viral RNA forms thanks to its capacity to accept mismatches.
The finding of the type III-A CRISPR-Cas system might influence how we think about bacterial evolution and create new medications. The evolution of bacteria, for instance, might have been impacted by this defense method. The variety of target sequences that the type III-A CRISPR-Cas system may address could also make it a good candidate for the development of new antiviral medications.
The type III-A CRISPR-Cas system's discovery may open the door to more research on bacterial immunity as well as the development of novel antiviral therapies. Additionally, it serves as a reminder of nature's complexity and inventiveness in the fight against illness.
